{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:02:28Z","timestamp":1790514148655,"version":"4.1.0"},"reference-count":25,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>The systemic capillary leak syndrome (SCLS), also known as Clarkson\u2019s disease, is a life-threatening disorder of unknown cause. It is characterised by recurrent acute episodes of hypotension, weight gain and generalised oedema with haemoconcentration and hypoproteinaemia caused by paroxysmal capillary hyperpermeability with a shift of plasma fluid from the intravascular to the interstitial space. We report the case of a 40-year-old woman with chronic SCLS treated with high-dose intravenous immunoglobulins, after a prophylactic therapy with theophylline and terbutaline was poorly tolerated and failed to decrease the frequency and severity of the attacks sufficiently.<\/jats:p>","DOI":"10.1136\/bcr.12.2010.3599","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T06:33:56Z","timestamp":1304404436000},"page":"bcr1220103599","source":"Crossref","is-referenced-by-count":15,"title":["High-dose intravenous immunoglobulins: A promising therapeutic approach for idiopathic systemic capillary leak syndrome"],"prefix":"10.1136","volume":"2011","author":[{"given":"Manuel","family":"Zipponi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Eugster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Birrenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(60)90018-8"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-130-11-199906010-00015","article-title":"Treatment of the systemic capillary leak syndrome with terbutaline and theophylline. A case series.","volume":"130","author":"Tahirkheli","year":"1999","journal-title":"Ann Intern Med"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.3","first-page":"179","article-title":"Le syndrome d\u2032hyperperm\u00e9abilit\u00e9 capillaire idiopathique","volume":"9","author":"Amoura","year":"1997","journal-title":"STV"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2005.12.011"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.5","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050700"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.6","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31817d7c71"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.3.492"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2009.01.005"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.46.6129"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.4.1301"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000227120.61949.FB"},{"issue":"11","key":"2025082623102643000_2011.apr27_1.bcr1220103599.12","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2.","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology (Williston Park, NY)"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-197705000-00004","article-title":"Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature.","volume":"56","author":"Atkinson","year":"1977","journal-title":"Medicine (Baltimore)"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2249.1993.tb08195.x","article-title":"The paraproteins in systemic capillary leak syndrome.","volume":"93","author":"Zhang","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00272-6"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.17","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90749-2"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.18","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1152\/jappl.1989.67.5.1997","article-title":"Permeability of human endothelial monolayers: effect of vasoactive agonists and cAMP.","volume":"67","author":"Casnocha","year":"1989","journal-title":"J Appl Physiol"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.19","doi-asserted-by":"publisher","DOI":"10.1159\/000008717"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1537-1891(03)00014-4"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.21","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.amjmed.2009.09.034","article-title":"Immunoglobulins for treatment of systemic capillary leak syndrome.","volume":"123","author":"Abgueguen","year":"2010","journal-title":"Am J Med"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.22","unstructured":"Fehr J Kazatchkine MD . Fc receptor blockade. In: Intravenous Immunoglobulins: Clinical Benefits and Future Prospects. Pearl River, NY: Parthenon Publishing Co 1994:37\u20138."},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood.V77.2.376.376","article-title":"High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes.","volume":"77","author":"Basta","year":"1991","journal-title":"Blood"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.06.043"},{"key":"2025082623102643000_2011.apr27_1.bcr1220103599.25","first-page":"211","article-title":"Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG.","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.12.2010.3599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:10:34Z","timestamp":1756275034000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.12.2010.3599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":25,"alternative-id":["10.1136\/bcr.12.2010.3599"],"URL":"https:\/\/doi.org\/10.1136\/bcr.12.2010.3599","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}